You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
NORTHBROOK, Ill., May 5, 2015 /PRNewswire/ -- Astellas announced that two abstracts detailing clinical data from studies of enzalutamide and one abstract detailing clinical data from a study of...
NORTHBROOK, Ill., April 27, 2015 /PRNewswire/ -- Astellas announced today that CRESEMBA® (isavuconazonium sulfate), the prodrug for isavuconazole, is now available in the United States for the...
Isolation and lack of one-on-one peer connection is the largest challenge facing millennial cancer patients and caregivers 15-39 years old NEW YORK and NORTHBROOK, Ill. (April 27, 2015) – The...
NORTHBROOK, Ill., April 23, 2015 /PRNewswire/ -- Astellas announced today that seven abstracts will be presented on CRESEMBA® (isavuconazonium sulfate), the prodrug for isavuconazole, at the 25th...
TOKYO, April 6, 2015 /PRNewswire/ -- Astellas ("Astellas,") (Tokyo: 4503) today announced that Dr. Shontelle Dodson has been named vice president, Medical Excellence, Medical Affairs. Dodson will...
Read more about Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function
Follow U.S. news
